Telix Pharmaceuticals (TLX) Receivables (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Receivables data on file, last reported at $130.5 million in Q4 2025.

• In Q4 2025, Receivables rose 40.27% year-over-year to $130.5 million; the TTM figure through Dec 2025 stood at $130.5 million (up 40.27% YoY), while the FY2025 annual figure was $130.5 million, up 40.27% from the prior year.
• Receivables climbed to $130.5 million in Q4 2025, from $93.0 million in the prior quarter.
• Across five years, Receivables topped out at $130.5 million in Q4 2025 and bottomed at $43.7 million in Q4 2023.
• A 3-year average of $89.1 million and a median of $93.0 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables jumped 112.85% — and 2025, when it jumped 40.27%.
• Year by year, Receivables stood at $43.7 million in 2023, then jumped by 112.85% to $93.0 million in 2024, then jumped by 40.27% to $130.5 million in 2025.
• The last three Receivables figures came in at $130.5 million (Q4 2025), $93.0 million (Q4 2024), and $43.7 million (Q4 2023), per Business Quant data.

Peer Comparison